Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Study Highlights How Industry Demand Is Evolving

The field of ribose-nucleic acid (RNA)-based therapeutics is gaining significant traction as it promises to revolutionize medical treatments across various diseases. With ongoing scientific advances and increasing investments, the market is positioned for remarkable growth over the coming years. Below, we examine the market's projected valuation, key companies involved, emerging trends, and the segmentation that defines this evolving industry.

Projected Growth and Market Size of the Ribose-Nucleic Acid (RNA)-Based Therapeutics Market
The RNA-based therapeutics market is expected to experience robust expansion, reaching a valuation of $26.17 billion by 2030. This growth translates to a compound annual growth rate (CAGR) of 8.7% during the forecast period. Several factors contribute to this upward trajectory, including a rise in regulatory approvals for RNA therapies, growing demand for personalized medicine, expansion in RNA pipelines targeting oncology, increased funding in advanced delivery technologies, and stronger collaboration efforts among biotech companies. Key market trends include the development of RNA-targeted therapies, the expanding use of siRNA and antisense oligonucleotide (ASO) technologies, intensified attention on rare and genetic diseases, growth in clinical trials, and continuous innovations in drug delivery systems.

The ribose-nucleic acid (rna)-based therapeutics market size has grown strongly in recent years. It will grow from $17.22 billion in 2025 to $18.75 billion in 2026 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to advancements in molecular biology research, initial success of rna-based drugs, expansion of genetic disease research, increased pharmaceutical r&d investments, growing understanding of gene regulation.

Download a free sample of the ribose-nucleic acid (rna)-based therapeutics market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18454&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Leading Players Driving the Ribose-Nucleic Acid (RNA)-Based Therapeutics Market
The competitive landscape consists of several influential organizations driving innovation and market expansion. Prominent companies in this space include F Hoffmann La Roche AG, Eli Lilly And Company, Novo Nordisk AS, Regeneron Pharmaceuticals, Biogen Inc., BioNTech, Alnylam Pharmaceuticals, Sarepta Therapeutics, Ionis Pharmaceuticals, Akcea Therapeutics Inc, Arrowhead Pharmaceuticals, Dicerna Pharmaceuticals, Wave Life Sciences, Quark Pharmaceuticals, Tekmira Pharmaceuticals, ReCode Therapeutics, Arbutus Biopharma Corporation, Benitec Biopharma Inc., Olix Pharmaceuticals, Alltrna Inc., Orbital Therapeutics, Moderna Inc., CureVac NV, Silence Therapeutics plc, and ProQR Therapeutics NV.

Notably, in May 2024, Orna Therapeutics, a US-based biotech firm focused on RNA therapeutics, acquired ReNAgade Therapeutics. While the financial terms were undisclosed, this strategic move aims to combine Orna's circular RNA expression technologies with ReNAgade's lipid nanoparticle (LNP)-based RNA delivery and editing platforms, strengthening their position in the RNA therapeutic market. ReNAgade Therapeutics also specializes in RNA-based treatment development, making this acquisition a complementary fit.

View the full ribose-nucleic acid (rna)-based therapeutics market report:
https://www.thebusinessresearchcompany.com/report/ribose-nucleic-acid-rna-based-therapeutics-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Emerging Trends Shaping the Future of RNA-Based Therapeutics
Innovation in mRNA technologies continues to be a driving force behind new therapeutic developments, especially for vaccines. Companies are advancing messenger RNA (mRNA)-based booster vaccines designed to improve immune responses, tackle emerging virus variants, and extend the protection duration offered by existing vaccines. This approach works by instructing cells to produce specific proteins that trigger targeted immune defenses.

For example, in June 2023, Gennova Biopharmaceuticals Ltd., an Indian pharmaceutical company, launched GEMCOVAC-OM, the country's first mRNA booster vaccine addressing the Omicron COVID-19 variant. This booster was introduced to overcome the reduced effectiveness of earlier vaccines against Omicron by enhancing immunity and providing better protection based on mRNA technology.

Segmentation Overview in the Ribose-Nucleic Acid (RNA)-Based Therapeutics Market
This market is segmented into several categories to better understand its scope and applications:

1) By Type:
- RNA Interference (RNAi)
- RNA Antisense

2) By Technology:
- Enabling Technology
- Enabled Technology

3) By Therapeutic Area:
- Oncology
- Genetic Disorders
- Ophthalmology
- Hematological Disorders
- Acute Hepatic Porphyria (AHP)
- Other Therapeutic Areas

4) By End User:
- Research Institutes
- Hospitals and Clinics

Further subcategories include:
- RNAi Type: Small Interfering RNA (siRNA) and MicroRNA (miRNA)
- RNA Antisense Type: Antisense Oligonucleotides (ASOs) and Antisense RNA

Together, these segments provide a comprehensive framework for analyzing the RNA therapeutics market, highlighting its diverse technological approaches, clinical applications, and user bases.

Key enhancements in our 2026 market reports include:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.